Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
OwnerChristen ANDERSON, Alain D. Baroninventors
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac myocytes and also to improving cardiac contractility.
Claims26
A method for preventing or ameliorating apoptosis of cardiac myocytes in a subject in need thereof, said method comprising administering to said subject an amount of a glucagon-like peptide-1 (GLP-1) molecule or agonist thereof effective to prevent apoptosis of cardiac myocytes.
A method for the treatment or prevention of a condition associated with cardiac myocyte apoptosis in a subject in need thereof, said method comprising administering to said subject an amount of a glucagon-like peptide-1 (GLP-1) molecule or agonist thereof effective to prevent cardiac myocyte apoptosis, wherein said condition associated with cardiac myocyte apoptosis is thereby improved.
A method for improving the efficiency of cardiac myocytes in a subject in need thereof, said method comprising administering to said subject an amount of a glucagon-like peptide-1 (GLP-1) molecule or agonist thereof to improve the efficiency of cardiac myocytes.
Dependencies are inferred from the claim text.